We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
- Authors
K. Jordan; A. Hinke; A. Grothey; W. Voigt; D. Arnold; H.-H. Wolf; H.-J. Schmoll
- Abstract
Abstract Goals of work  Comparing antiemetic efficacy of different 5-HT3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV). Patients and methods  Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based). Main results  When all studies were combined, granisetron was equivalent to ondansetron (nâ=â27), and showed an advantage vs tropisetron (pâ=â0.018; nâ=â12). Ondansetron vs tropisetron (nâ=â11) and ondansetron vs dolasetron (nâ=â3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (pâ=â0.015; nâ=â6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (nâ=â13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (nâ=â6). No differences were seen between 3 and 1 mg granisetron doses (nâ=â6). Conclusions  Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.
- Publication
Supportive Care in Cancer, 2007, Vol 15, Issue 9, p1023
- ISSN
0941-4355
- Publication type
Academic Journal
- DOI
10.1007/s00520-006-0186-7